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Neurodegenerative disorders progress across the brain in characteristic spatio-temporal patterns. A better un-
derstanding of the factors underlying the speciﬁc cell and tissue vulnerability responsible for such patterns could
help identify the molecular origins of these conditions. To investigate these factors, based on the observation that
neurodegenerative disorders are closely associated with the presence of aberrant protein deposits, we made the
hypothesis that the vulnerability of cells and tissues is associated to the overall levels of supersaturated proteins,
which are those most metastable against aggregation. By analyzing single-cell transcriptomic and subcellular
proteomics data on healthy brains of ages much younger than those typical of disease onset, we found that the
most supersaturated proteins are enriched in cells and tissues that succumb ﬁrst to neurodegeneration. Then, by
focusing the analysis on a metastable subproteome speciﬁc to Alzheimer's disease, we show that it is possible to
recapitulate the pattern of disease progression using data from healthy brains. We found that this metastable
subproteome is signiﬁcantly enriched for synaptic processes and mitochondrial energy metabolism, thus
rendering the synaptic environment dangerous for aggregation. The present identiﬁcation of protein supersatu-
ration as a signature of cell and tissue vulnerability in neurodegenerative disorders could facilitate the search for
effective treatments by providing clearer points of intervention.1. Introduction
Alzheimer's disease (AD); the primary cause of dementia, affects over
50 million people worldwide (De Strooper and Karran, 2016; Holtzman
et al., 2011; Knowles et al., 2014; Selkoe and Hardy, 2016). The nature
and the origins of this disease are still not known with certainty, as its
onset and progression have been associated with a variety of factors,
including mitochondrial dysfunction, disruption of the endoplasmic re-
ticulum and membrane trafﬁcking, disturbances in protein folding and
clearance, and the activation of the inﬂammatory response (De Strooper
and Karran, 2016; Holtzman et al., 2011; Knowles et al., 2014; Selkoe
and Hardy, 2016). Despite this complexity, at the histopathological level
AD is clearly associated with a characteristic pattern of progression
across the brain, known as Braak staging (Bero et al., 2011; Braak and
Braak, 1991; Mattson and Magnus, 2006; Miller et al., 2013). AD is
hallmarked by aberrant deposits, known as amyloid plaques and neuro-
ﬁbrillary tangles, which are primarily composed of the amyloid betacolo).
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evier Ltd. This is an open access apeptide (Aβ) and the tau protein, respectively (De Strooper and Karran,
2016; Holtzman et al., 2011; Knowles et al., 2014; Selkoe and Hardy,
2016). The formation of these deposits has been implicated with the
cellular dysregulation of protein homeostasis within affected tissues
(Balch et al., 2008; Brehme et al., 2014; Gidalevitz et al., 2006; Hartl
et al., 2011; Labbadia and Morimoto, 2015).
The speciﬁc staging of the disease and the presence of protein ag-
gregates are characteristic not just of AD, but also of a wider range of
neurodegenerative disorders, including Parkinson's disease (PD), fron-
totemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)
(Balch et al., 2008; Brehme et al., 2014; Eisenberg and Jucker, 2012;
Hartl et al., 2011; Knowles et al., 2014; Labbadia and Morimoto, 2015).
Therefore, by investigating the relationship between tissue vulnerability
and the phenomenon of protein aggregation one could hope to obtain
insights into the molecular origins of these diseases. We have recently
shown that tissues vulnerable to AD can be characterised by the
expression levels of a set of proteins comprising those that co-aggregater 2019
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
Fig. 1. Schematic illustration of the calculation process to obtain the Δ scores.
Multiple probes are used to measure the expression of each gene. For each probe
p for a gene g expression is measured in each region r in the brain. Expression
values for each probe are normalised across all tissues by subtracting the
average value of the expression and by dividing the result by the standard de-
viation of the expression (Eq. 1). This step is carried out to enable the combi-
nation of expression readings from different probes. The Δ score of a probe (Δp)
is calculated by subtracting the mean expression in non-Braak regions (NB) from
the mean expression in a regional subset (R) of interest (Eq. 2). Finally, a Δ score
for a gene (Δg) is calculated by averaging Δ scores from the corresponding
probes (Eq. 5). We veriﬁed over a total of 18,918 genes that two probes
measuring the same gene were highly correlated (coefﬁcient of correlation
R  0.7).
R. Freer et al. Heliyon 5 (2019) e02589to form plaques and tangles, and those that modulate the aggregation of
Aβ and tau (Freer et al., 2016; Fu et al., 2019). Together, the expression
levels of these proteins recapitulate the speciﬁc pattern of disease pro-
gression in AD (Freer et al., 2016).
Given that these results implicate dysregulation of protein aggrega-
tion in tissue vulnerability to AD, here we ask whether there are other
proteins that place a burden on the protein homeostasis system. We
focused attention on supersaturated proteins: proteins that are poorly
soluble at the concentrations at which they are expressed. We posited
that the presence of a speciﬁc subset of supersaturated proteins may
impact the capacity of the protein homeostasis system to control aggre-
gation, thus favoring the creation of an environment vulnerable to
disease-speciﬁc aggregation. To identify this set of proteins, we began by
investigating the role played by supersaturation in deﬁning an environ-
ment vulnerable to the inception of neurodegenerative disease. In
alignment with a role in vulnerability to aggregation, highly supersatu-
rated proteins were found to be enriched in plaques and tangles, and in
the aggregates found in ageing worms (Ciryam et al., 2013, 2015).
By exploiting recent advances in single-cell transcriptomics (Darma-
nis et al., 2015) and in subcellular proteomics (Wilhelm et al., 2014), the
results that we report here indicate that cell and tissue vulnerability to
neurodegeneration is associated with the elevated expression of a com-
mon set of highly supersaturated proteins. We further show that in AD,
Braak staging is associated with the elevated expression of a set of
metastable subproteome speciﬁc to Alzheimer's, which is composed of
proteins that are supersaturated and downregulated in the disease. To
explain why brain tissues, and neurons in particular, are so vulnerable to
protein aggregation, we show that the metastable proteins are closely
involved in synaptic processes, resulting in a vulnerability of the synaptic
environment to aberrant protein aggregation.
2. Results
2.1. Superaturated proteins are enriched in cells and tissues vulnerable to
neurodegenerative processes
In order to investigate the link between protein aggregation and
neurodegenerative disorders, we ﬁrst asked whether the vulnerability to
neurodegenerative processes can be associated with a sustained burden
on the protein homeostasis system (Balch et al., 2008; Brehme et al.,
2014; Hartl et al., 2011; Knowles et al., 2014), resulting from a presence
above average of aggregation-prone proteins (Gidalevitz et al., 2006;
Labbadia and Morimoto, 2015; Olzscha et al., 2011; Vendruscolo, 2012;
Walther et al., 2015).
Following these considerations, we hypothesised that supersaturated
proteins, which are expressed beyond their solubility limits, may have a
role in tissue vulnerability to aberrant aggregation in neurodegenerative
processes. We thus sought to establish whether such proteins may be
found at elevated levels in those brain tissues most vulnerable to
neurodegenerative processes in samples obtained from healthy brains
much before the typical onset of disease. To address this question we
utilised data from the Allen Brain Atlas and theΔ score method (Fig. 1) to
quantify differential expression (Freer et al., 2016). The Δ scores repre-
sent the expression levels in vulnerable tissues relative to those in
resistant tissues (see Experimental Procedures and Table S1 for a list of
disease-speciﬁc vulnerable regions).
For this analysis we used mRNA expression data to estimate protein
levels because, despite recent advances (Uhlen et al., 2015), systematic
data concerning protein levels across different brain regions at high level
of granularity are not yet available. Although it is well known that at the
level of individual genes the correlation betweenmRNA expression levels
and protein abundance levels is typically weak, here we are interested in
averages over groups of genes, for which the correlation with the cor-
responding groups of proteins can be much stronger (Fig. 2). The Allen
Brain Atlas is an online repository of microarray data for six normal
human brains of ages 24–56 (Hawrylycz et al., 2012). Over 5002measurements are taken for each individual, with 93% of known genes
represented by at least two probes. To evaluate the extent of noise in this
dataset, we calculated the correlation between gene differential expres-
sion measured using different probes, as quantiﬁed by the Δ score (see
Experimental Procedures), ﬁnding a good agreement between Δ scores
for two probes measuring the same gene, with a Pearson coefﬁcient of
correlation of 0.7 (Fig. 3). To estimate the supersaturation levels, we used
the measured expression levels of the genes relative to a
computationally-derived aggregation propensity score as previously
(Ciryam et al., 2013). For the analysis that follows we refer to supersat-
urated proteins as those in the top 5% of the distribution of supersatu-
ration scores (Table S2).
We ﬁrst investigated the role played by these supersaturated proteins
in deﬁning the tissues most vulnerable to neurodegenerative processes,
for example certain regions of the hippocampus in AD (Table S1). By
carrying out a Δ score analysis (Table S3), we found that in those tissues
Fig. 2. Analysis of the average correlation between mRNA and protein levels. (A) Correlation between mRNA and protein levels for two representative regions of the
brain (Uhlen et al., 2015). (B) Correlation between mRNA and protein levels, averaged data. Error bars are smaller than the data point symbols. The correlation
coefﬁcients between mRNA levels and protein levels for hippocampal and cerebral cortex tissues are 0.98 (p ¼ 0.02) in both cases. Protein expression levels are
derived from immunohistochemical data scored according to staining intensity (negative, weak, moderate or strong), and fraction of stained cells (low (<25%),
medium (25–75%) or high (>75%)). Each combination of intensity and fractions is converted into a protein expression level score as follows: negative – not detected;
weak/low – not detected; weak/medium or weak/high – low; moderate/low – low; moderate/medium or moderate/high – medium; strong/low – medium,
strong/medium or strong/high – high. (C) Measured levels of total tau protein (Causevic et al., 2010), normalised to actin levels. The expression score for each region
is relative to non-Braak tissues. C: cerebellum; EC: entorhinal cortex; OC: occipital cortex; STG: superior temporal gyrus; FC: frontal cortex and H: hippocampus. (D)
Relative mRNA levels for the MAPT gene, for corresponding brain regions. The correlation coefﬁcient between relative MAPT mRNA levels and relative tau protein
levels is 0.9 (p ¼ 0.01). Boxes represent the ﬁrst and third quartiles of the distribution, whiskers the 1.5 inter-quartile range, and notches are standard errors on the
median calculated with 100 bootstrap cycles. *****p < 0.00001, calculated with a Mann-Whitney U test with Benjamini-Hochberg multiple hypothesis testing
correction (Benjamini and Hochberg, 1995). Protein expression scoring in (A) and (B) are based is based on immunohistochemical data manually scored with regard to
staining intensity (negative, weak, moderate or strong), and fraction of stained cells (Uhlen et al., 2015).
Fig. 3. Test of the level of noise in the Allen Brain Atlas dataset. The correlation
between Δ scores for two probes measuring the same gene was tested, resulting
in a coefﬁcient of correlation of 0.7.
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saturated proteins (Table S2) are on average a signiﬁcantly more
expressed than in resistant tissues (Fig. 4).
Overall, we found a broad agreement between the regional vulnera-
bility to neurodegenerative processes (Table S1) and the tissue-speciﬁc
expression levels of the genes encoding for supersaturated proteins
(Fig. 4A). The underlying data plotted for individual diseases highlight
that high differential expression is observed for the supersaturated pro-
teins, but not for the proteome as a whole (Fig. 4B). In the case of AD, we3further veriﬁed that these results are not signiﬁcantly affected by the
imperfect mapping between Braak regions and Allen Brain Atlas regions
(see Experimental Procedures) and by an under-representation of white
matter tissue (see Experimental Procedures) in the datasets that we used
(Fig. 5).
The levels of expression of supersaturated proteins are not only
closely linked to vulnerability at the tissue level, but also at the cell-type
level. From an analysis of single cell human RNAseq data (see Experi-
mental Procedures), we found that neurons have levels of supersaturated
proteins that are signiﬁcantly more elevated than those observed in other
brain cell types (Fig. 6). Thus, building on previous reports that super-
saturated proteins are enriched in the characteristic aggregates observed
in neurodegenerative diseases (Ciryam et al., 2015), these results
demonstrate that supersaturated proteins preferentially localise to tissues
and cell types most vulnerable in disease.2.2. A metastable subproteome speciﬁc to AD predicts tissue and cell
vulnerability to AD
Having found an association between the regional expression levels of
the most supersaturated proteins and tissue vulnerability to neurode-
generative processes, we next sought to assess the role of a metastable
subproteome speciﬁc to AD (Ciryam et al., 2016). We predicted the ex-
istence of a subproteome metastable against aggregation, with potential
to create an environment conducive to protein aggregation characteristic
Fig. 4. In healthy brains, supersaturated
proteins are highly expressed in tissues and
cells vulnerable to neurodegenerative pro-
cesses. (A) Red regions in the brain on the left
indicate an elevated expression of supersatu-
rated proteins relative to the proteome, while
blue regions indicate an average expression
below that of the proteome as a whole. Red
regions in the brain on the right indicate the
tissues most vulnerable to neurodegenerative
processes associated with the early stages of
AD, PD, FTD and ALS (see panel B and
Table S1). (B) Box plot of Δ scores of the top
5% of supersaturated proteins (red) compared
to the whole proteome (grey) calculated for
AD, PD, ALS and FTD (x-axis). For each dis-
ease, Δ scores represent expression in
vulnerable tissues, relative to expression in
resistant tissues (see Experimental Proced-
ures). The Δ scores reported for PD, ALS and
FTD are calculated with the same procedure
described in Experimental Procedures for AD,
using the disease-speciﬁc vulnerable regions
deﬁned in Table S1. *****p < 0.00001; the
statistical signiﬁcance of the differences be-
tween the distributions of supersaturated
proteins and that of the proteome was calcu-
lated with a t-test. In addition, a one tailed t-
test was used to test that the distribution of
relative expression scores for supersaturated
proteins is greater than zero. This test yielded
a p value of less than 0.00001 for tissues
vulnerable to AD, PD, ALS and FTD. The
dashed line at Δ ¼ 0 (NV) indicates non-
vulnerable tissues.
R. Freer et al. Heliyon 5 (2019) e02589to AD. We deﬁned this metastable subproteome as the intersection be-
tween highly supersaturated proteins, proteins downregulated in ageing,
and proteins downregulated in disease (Ciryam et al., 2016); it contains
77 proteins (Fig. 7A and Table S2). The progression of AD across brain
regions was determined using the Braak staging (Braak and Braak, 1991),
which relies on the histopathological examination of the distribution of
tangles in the brain during subsequent stages of AD, which is known to
correlate with neuronal atrophy (Whitwell et al., 2008).4Using the Δ score analysis, we found that this metastable sub-
proteome has signiﬁcantly elevated expression in the tissues most
vulnerable to AD (tissues of Braak stages I-III) with respect to the other
tissues (Fig. 7B and Tables S4 and S5). These results extend those that we
previously reported, where we found that the speciﬁc set of proteins
found in plaques and tangles in AD brains are also supersaturated (Cir-
yam et al., 2013). We established that these ‘co-aggregators’ had a
signiﬁcantly elevated expression in early AD tissues, however they could
Fig. 5. Distributions of ΔB scores for tissues of consecutive Braak stages. (A)
Boxplots of the ΔB scores for the metastable subproteome calculated for ‘perfect
match’ tissues (see Table S8) progressively affected by AD (x-axis). (B) Same
data as for panel A, but for all tissues. A comparison of ΔB score distributions is
presented with white matter data included (left) and excluded from analysis
(right). For each boxplot, the signiﬁcance of the difference between ΔB distri-
butions for Braak I-III and Braak IV-VI datasets, and for Braak IV-VI and non-
Braak (NB) datasets was calculated with a Mann-Whitney U test and Benjamini-
Hochberg multiple hypothesis testing correction (Benjamini and Hochberg,
1995) *****p < 0.00001.
Fig. 6. Relative expression of supersaturated proteins in different cell types.
Expression analysis was carried out on human single cell RNAseq data (Dar-
manis et al., 2015). For further details on analysis method see Experimental
Procedures. The p-value describes the signiﬁcance of expression in neurons,
relative to that in other brain cell types plotted, calculated with the
Mann-Whitney U test with Benjamini-Hochberg multiple hypothesis testing
correction (Benjamini and Hochberg, 1995) *****p < 0.0005.
R. Freer et al. Heliyon 5 (2019) e02589not predict differential vulnerability between tissues (Freer et al., 2016).
We next sought to use relative metastable subproteome expression to
assess vulnerability to AD for different cell types. By calculating the
relative expression of the metastable subproteome for different brain
cells, utilising human single cell RNAseq data (Darmanis et al., 2015), we
found that neurons have signiﬁcantly higher levels of
metastable-subproteome proteins than astrocytes, microglia and
brain-derived endothelial cells (Fig. 7C).
To test the robustness of our deﬁnition of metastable subproteome,5we considered a range of alternative deﬁnitions corresponding to
different overlaps between highly supersaturated proteins and proteins
corresponding to genes with high relative expression in Braak I-III re-
gions. We conﬁrmed that a signiﬁcant number of genes that intersect the
top 5% of these two subsets, are also downregulated in AD and upon
ageing. In contrast, signiﬁcantly fewer of those genes in the intersection
between the bottom 5% of ΔBI-III scores and the supersaturated proteins
are downregulated in ageing and disease (Fig. 8 and Table S2). These
results are fully consistent with those discussed above, and suggest that
by analysing two properties that can be measured in normal brains (su-
persaturation and expression levels in early Braak regions), one can make
predictions about tissue vulnerability to AD.
Taken together, the results that we have presented in this section
indicate that tissue and cell vulnerability to AD is associated with the
elevated expression of a metastable subproteome speciﬁc to AD. These
results are consistent with previous single-nucleus RNA-seq analysis
demonstrating that this metastable subproteome has signiﬁcantly
elevated expression in a neuronal subset with high relative vulnerability
to degeneration in AD (Fu et al., 2019).
2.3. The synaptic environment is highly vulnerable to protein aggregation
To investigate vulnerability to neurodegenerative processes at a level
of granularity more precise than tissue classiﬁcation, we next focused on
the expression signatures of cell types and subcellular localisations.
Exploiting recent advances in proteomics, which enabled the systematic
quantiﬁcation of protein levels in synaptosomes (Wilhelm et al., 2014),
we investigated whether our ﬁndings can also help rationalize why
neuronal synapses succumb particularly early in neurodegerative dis-
eases (Bero et al., 2011; De Strooper and Karran, 2016; Muratore et al.,
2017).
We found that both supersaturated proteins and the metastable sub-
proteome have elevated expression in neurons relative to other cell types
(Figs. 2C and 6), and the metastable subproteome is signiﬁcantly
enriched in the synaptosome relative to whole neurons (Fig. 7C).
Robustness tests conﬁrm the enrichment of synaptosomal proteins in the
metastable subproteome, relative to the proteome as a whole (Fig. 9A).
To further investigate these results, we identiﬁed a subset of proteins that
we predicted to be more metastable than the proteome as a whole, but
less aggregation prone than the metastable subproteome. We termed the
members of this subset ‘intersectional proteins’. Intersectional proteins
are deﬁned as those that belong to at least two groups among supersat-
urated, downregulated in AD, and downregulated in ageing, but are not
part of the metastable subproteome. We found that intersectional pro-
teins have a signiﬁcantly elevated enrichment for synapsosomal local-
isation, but with an enrichment ratio smaller than that of the metastable
proteome (Fig. 9A).
Having established an enriched presence of metastable proteins in the
synaptosome set, we next sought to understand the abundance of meta-
stable subproteome components in the synapse, by analysing mass-
spectrometry data from isolated synaptic derivatives (Wilhelm et al.,
2014). We consistently found that the metastable subproteome is highly
abundant in the synaptosome for all metrics tested (Fig. 9B).
The prevalence of supersaturated proteins in the synaptic environ-
ment is particularly well illustrated by comparing the supersaturation of
the synaptosome relative to the proteome (Figs. 10 and 11), and the
abundance and localization of the synaptic proteins that are most su-
persaturated, including synaptotagmin, snap25, AP180 and tangle co-
aggregator Hsc70 (Wang et al., 2005) (Fig. 10 and Movie S1). It is
remarkable that supersaturated proteins are enriched at synapses relative
to whole neurons, given that early synaptic degeneration has been
observed in AD (Coleman et al., 2004; Selkoe, 2002).
Overall, the results that we presented in this section indicate that the
vulnerability of speciﬁc cell types and subcellular localisations to AD is
correlated with the elevated expression at neuronal synapses of a com-
mon set of highly supersaturated proteins, which places the environment
Fig. 7. The expression of a metastable sub-
proteome speciﬁc to AD is elevated in cell
types and tissues vulnerable to AD. (A) The
AD-speciﬁc metastable subproteome is
deﬁned as the intersection of three sets of
proteins; those downregulated with age,
downregulated in AD, and highly supersatu-
rated (B) Comparison of the distributions of
the Δ scores of genes comprising the meta-
stable subproteome (MS, red) and the whole
proteome (grey) (C) Expression of the meta-
stable subproteome relative to the expression
of the proteome in brain cell types and syn-
aptosomes. ‘Other cell types’ include astro-
cytes, brain-derived endothelial cells, and
microglia. For further details on analysis
method see Experimental Procedures. *p <
0.01, *****p < 0.00001, Mann Whitney U-
test (Benjamini and Hochberg, 1995).
Fig. 8. Test of the robustness of the results
against the deﬁnition of the metastable sub-
proteome. (a) Difference in overlap size be-
tween proteins downregulated in disease and
supersaturated, and proteome members with
top and bottom 5% ΔBI-III scores. (b) Differ-
ence in overlap size between proteins down-
regulated in ageing and supersaturated, and
proteome members with top and bottom 5%
ΔBI-III scores. (c) Sizes of all intersections
related to panels (a) and (b). *****p <
0.0001, Fisher exact test performed for panels
(a) and (b).
R. Freer et al. Heliyon 5 (2019) e02589
6
Fig. 9. Metastable subproteome proteins are
signiﬁcantly more abundant at the synapse
than intersectional proteins and, more gener-
ally, the synaptosome. (A) Enrichment of the
metastable subproteome (MS, left), and
intersectional proteins (right), with respect to
the most abundant synaptosomal proteins.
Intersectional proteins are deﬁned as those
that belong to at least two groups among su-
persaturated, downregulated in AD, and
downregulated in ageing, but are not part of
the metastable subproteome. (B) Concentra-
tion, copy number, and percentage for the
metastable subproteome (red), intersectional
proteins (blue), and all proteins measured in a
synaptic buton (grey). ***p < 0.01 and
*****p < 0.0001, Fisher exact test performed
for panel A; *p < 0.05, **p < 0.01 Mann-
Whitney U test performed for panel B (Ben-
jamini and Hochberg, 1995).
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Fig. 10. Section a synaptic buton illustrating the high protein supersaturation
levels in this environment. A supersaturation score quantiﬁes the expression of a
protein relative to its solubility limit (Ciryam et al., 2013). Proteins in red
have supersaturation scores above the 90th percentile for the proteome as a
whole. Proteins in blue have scores below the 40th percentile. Details on the
proteomic contents of the synaptic buton are taken from a previous study
(Wilhelm et al., 2014). Details on the ﬁgure conﬁguration are given in Experi-
mental Procedures.
Fig. 11. The synaptic environment is enriched in aggregation-prone proteins.
Cumulative distribution function (CDF) of supersaturation scores of the synap-
tosome and the proteome. The statistical signiﬁcance of the difference between
the mean values of the distributions is evaluated using a t-test, p ¼ 1  1018.
Details on the proteomic contents of the synaptic buton are taken from a pre-
vious study (Wilhelm et al., 2014).
R. Freer et al. Heliyon 5 (2019) e02589at risk to protein aggregation.2.4. The metastable subproteome speciﬁc to AD is primarily involved in
synaptic processes
We next sought to understand the physiological role of the metastable
subproteome speciﬁc to AD. Using enrichment analysis of biological
processes (see Experimental Procedures), we found that the metastable
subproteome plays a key role in biochemical pathways associated with
synaptic functions, including ion transport, and synaptic transmission, as
well as more generally with mitochondrial energy metabolism (Fig. 12
and Tables S6 and S7). Enrichment ratios were calculated as the ratio
between observed and expected values for each category (see Experi-
mental Procedures). Then, using enrichment analysis of subcellular
localisations we found that the metastable subproteome is particularly
highly expressed at synapses and in proximity of lipid membranes of8neurons (Fig. 12 and Tables S6 and S7). These results complement those
reported in Fig. 10, as they show that the synaptic environment is
enriched in aggregation-prone proteins due to its physiological functions.
The results in this section thus indicate that the metastable proteins at
risk of aggregation in AD are particularly involved in synaptic processes,
which provides insights into the molecular origins of synaptic loss in AD.
We also note that although the contributions of mitochondria to neuro-
degeneration has long been recognised, the precise mechanism of path-
ogenesis remains unclear (Gillingwater andWishart, 2013; Wishart et al.,
2006). Our results indicate that elevated levels of mitochondrial proteins
can contribute to the metastability of a protein environment, conferring
synaptic vulnerability independent to mitochondrial function.2.5. Metastable subproteome levels in healthy brain tissues predict the
progression of AD
Finally, we sought to assess whether expression levels of the meta-
stable subproteome in normal brains, decades before ages typical of
disease onset, could predict the progression of AD. We posited that this
relationship would be observed due to a similar mechanism to that we
previously reported for the expression levels of components of the pro-
teostasis system that regulates the amyloid beta peptide and tau (Freer
et al., 2016). Using the Δ score analysis, we found that the most
vulnerable tissues to AD (i.e. the early Braak tissues) have signiﬁcantly
elevated relative expression levels of the proteins in the metastable
subproteome (Fig. 13). In addition, we found that the relative expression
is lower in tissues with progressively more AD resistance, which succumb
at later stages of the disease (late Braak tissues) (Fig. 13B and Table S8).
It is possible that progressive neuronal death during AD progression
could partly account for the trend in Fig. 13B, as the metastable sub-
proteome, which is highly expressed within neurons, is derived from
genes downregulated in AD (Ciryam et al., 2016). To control for this
possibility, we calculated the Δ scores across progressive Braak stage
tissues for genes downregulated in AD, but not supersaturated, nor
downregulated with age (Fig. 14). We found no signiﬁcant trend across
the Braak stages, indicating that measurements of downregulation of
gene expression during AD are not markedly affected by neuronal atro-
phy in vulnerable tissues.
Overall, the results described in this section indicate that the levels of
proteins in the metastable subproteome recapitulate the typical pro-
gression of AD across the brain described by the Braak staging. These
results build on previous work which demonstrates that levels of proteins
known to co-aggregate in Alzheimer's and their associated molecular
chaperones predict AD progression in normal brains (Freer et al., 2016).
Together, these studies collectively support a key role for protein su-
persaturation within the neuronal environment in determining vulnera-
bility to the onset of AD.
3. Conclusions
We have reported evidence that protein supersaturation underlies
vulnerability to aberrant aggregation in neurodegenerative processes,
and shown that supersaturated proteins are expressed at elevated levels
in the cell and tissues that ﬁrst succumb to neurodegenerative diseases.
We have then deﬁned a metastable subset of proteins speciﬁc to AD and
shown that these proteins are involved in synaptic processes and mito-
chondrial energy metabolism.
These results reveal that the synaptic environment is conducive to
protein aggregation, and offer a method of predicting the progression of
AD through the brain. By contributing to the identiﬁcation of the mo-
lecular origins of cell and tissue vulnerability to neurodegenerative dis-
eases, these results could provide clearer points of intervention related to
protein supersaturation to develop increasingly effective therapeutic
strategies.
Fig. 12. Synaptic processes and mitochondrial energy metabolism are enriched in metastable proteins. (A) Metastable subproteome enrichment ratio plotted against
enrichment signiﬁcance (p-value) for biological processes (left) and subcellular localisations (right). Point colours indicate the categories of the different processes, as
in the legend of panel D (see also Tables S6–S7). (B) Metastable subproteome enrichment in speciﬁc subcellular localisations, categorized as in (A). Green shading
coincides with subcellular localisations relevant to ion transport. (C) Enrichment ratio for the most signiﬁcantly enriched biological processes (D) Chart showing the
relative number of signiﬁcantly enriched biological process categories, organized into the broad classiﬁcations indicated. *p < 0.05, **p < 0.01, ***p < 0.01, ****p <
0.001 and *****p < 0.0001 one tailed Fischer exact test and Bonferroni multiple hypothesis correction (Benjamini and Hochberg, 1995).
R. Freer et al. Heliyon 5 (2019) e025893.1. Experimental Procedures
3.1.1. Data sources
A full list of data sources for the results reported in this work is
provided in Table S9.
3.1.2. Allen Brain Atlas
We analyzed data from six normal human brains from individuals
aged 24–57 years at the time of death. Samples were taken from more
than 500 regions for each hemisphere, and more than 19,700 genes were
studied with multiple probes. Microarray data were downloaded from
the Allen Brain Atlas (Hawrylycz et al., 2012) on 19 December 2014.
UniProt data (UniProt Consortium, 2014) for subcellular localization and
biological process gene ontology assignments were downloaded from
www.uniprot.org/downloads on 21 May 2015. Protein IDs were con-
verted between UniProt and Entrez ID (used by the Allen Brain Atlas)
using the UniProt ID mapping service. With this procedure, expression
data were assigned to about 90% of the human reference proteome.
3.1.3. Braak staging
At progressive clinical stages of AD, conserved patterns of deposition
of neuroﬁbrillary tangles in brain tissue are observed, with increasingly
large areas of the brain affected with advancing stages (Braak and Braak,
1991). In the Braak staging of AD (Braak and Braak, 1991), tissues are9classiﬁed according to when, in the progression of AD, neuroﬁbrillary
tangles appear in neuron. This method is employed because the forma-
tion of neuroﬁbrillary tangles is a pathological hallmark of AD, and
correlates well with cell atrophy (Whitwell et al., 2008). In Braak stages I
and II, the involvement of neuroﬁbrillary tangles is conﬁned primarily to
the transentorhinal region of the brain. In stages III and IV, limbic regions
are also affected, with all regions of the hippocampus exhibiting AD
pathology. In stages V and VI, there is extensive neocortical involvement.
Even at late stages of AD, some regions of the brain, notably the cere-
bellum, remain unaffected; we classiﬁed these regions as ‘non-Braak’
(NB). In the original paper describing the Braak staging (Braak and
Braak, 1991), disease stages were discussed sequentially, with the re-
gions affected noted at each stage, in addition to the severity of the pa-
thology in these regions.
3.1.4. Mapping between the Braak staging and the Allen Brain Atlas
To assign the brain regions from the Allen Brain Atlas to a corre-
sponding Braak stage, a rubric was developed. First, regions mentioned
in the original paper (Braak and Braak, 1991), which we refer to as ‘Braak
staging’ regions, were assigned to the earliest Braak stage that they are
associated with. Next, these regions were matched to the regions char-
acterized in the Allen Brain Atlas. When a region in the Allen Brain Atlas
was larger than a Braak staging region, the whole of the Allen Brain Atlas
region was allocated to the corresponding Braak stage. For instance,
Fig. 13. The metastable subproteome
expression in healthy tissues recapitulates the
progression of AD. (A) In the left panels, re-
gions are coloured by the mean Δ score for
metastable subproteome expression. In the
right panels, regions are coloured according
to Braak stage (see legend). (B) Box plot with
Δ scores for the metastable subproteome (MS)
in ‘perfect match’ regions affected at the
different Braak stages (x-axis). Perfect match
tissues have an optimal topological corre-
spondence between their Braak and Allen
Brain Atlas perimeters. **p < 0.01 and *****p
< 0.00001 p-values for B, calculated with
Mann-Whitney U test with Benjamini-
Hochberg multiple hypothesis testing correc-
tion (Benjamini and Hochberg, 1995). The
dashed horizontal line represents the Δ score
of non-Braak regions, which is zero by
deﬁnition.
R. Freer et al. Heliyon 5 (2019) e02589although only two isocortical layers were affected in Braak stage III, all
isocortical tissues were assigned to Braak stage III because isocortical
expression data were not distinguished by the layer they came from in the
Allen Brain Atlas parcellation. For this reason, in the present investiga-
tion of the relationship between Braak staging and gene expression sig-
natures, ‘perfect-match’ regions provide the most accurate data.
Perfect-match tissues have a high correspondence between their Braak
and Allen Brain Atlas perimeters. Assignments from Braak to Allen Brain
Atlas regions are listed in Table S4. The same method was used to map
tissues most vulnerable to AD, PD, FTD and ALS to the Allen Brain Atlas.
These assignments are listed in Table S1.
Of the two main types of tissue in the brain, white matter consists10mostly of glial cells and myelinated axons, whereas gray matter has a
more diverse composition, including neuronal cell bodies, dendrites,
myelinated and unmyelinated axons, glial cells, synapses, and capillaries.
Thus, because neuroﬁbrillary tangles are not found in AD in the axon
hillock or initial axon segment, one would not expect to see them in white
matter in AD (Fink, 2000). However, the volume of white matter does
shrink in some regions during the progression of AD, where affected
neurons have their cell bodies in gray matter and their axons in corre-
sponding white matter. This fact implies that the appearance of neuro-
ﬁbrillary tangles, and thus the Braak staging, may not be ideal for
describing vulnerability to AD in white matter tissues. However, the ef-
fect of this caveat on our study is limited because only 2 of the more than
Fig. 14. Distributions of ΔB scores for tissues assigned to consecutive Braak
stages, for a subset of genes downregulated in AD. Boxplots of the ΔB scores for
genes downregulated in AD, but not supersaturated nor downregulated in
ageing. Boxplots are calculated for tissues progressively affected by AD (x-axis).
For each boxplot, the signiﬁcance of the difference with the prior ΔB distribution
for non-Braak (NB) tissues was calculated with a Mann-Whitney U test and
Benjamini-Hochberg multiple hypothesis testing correction (Benjamini and
Hochberg, 1995).
R. Freer et al. Heliyon 5 (2019) e02589500 regions studied in the Allen Brain Atlas include white matter. In
Fig. 5b, the impact of white matter on observed results is tested and
shown to be non-signiﬁcant.
3.1.5. The Δ score of the expression of a gene
Because the expression of a given gene in the Allen Brain Atlas is
measured by multiple probes (Hawrylycz et al., 2012), we ﬁrst normal-
ized the expression reading Ep,r for each probe p in each region r in the
Allen Brain Atlas as
Erp;r ¼
Ep;r  μp
σp
(1)
where μp and σp are the average and standard deviation of Ep,r across all
regions, respectively. To quantify the variability of gene expression be-
tween tissues, we deﬁned a Δ score (Figure S1) for a given probe p over a
brain region R (which is typically made up of several Allen Brain Atlas
regions) as
Δp;R ¼ E'p;R  E'p;NB (2)
where
E'p;NB¼
1
NNB
XNNB
r¼1
E'p;r (3)
is the average of Ep,r for the non-Braak regions, that is, those regions that
do not map onto any Braak staging regions (Braak and Braak, 1991), and
E 'p;R¼
1
NR
XNR
r¼1
E'p;r (4)
represents the average of Ep,r over the set of Allen Brain Atlas regions
mapped onto brain region R under scrutiny (for example, a Braak stage).
Then, Δ scores for different probes measuring the same gene were
averaged to give a gene Δ score
Δg;R ¼ 1NpðgÞ
XNpðgÞ
g¼1
ΔR;pðgÞ (5)
where the average is over the Np(g) probes p(g) used to measure a gene g.
The full list of Δ scores for the genes analysed in this work is given in
Tables S3, S5 and S8. A comparison of Δ scores calculated for perfect-11match tissues is given in Table S8.
3.1.6. Deﬁnition of a subset of highly supersaturated proteins
The supersaturation scores for about 20,000 proteins were calculated
by quantifying measured tissue expression relative to a computationally-
derived solubility score (Ciryam et al., 2013). The proteins making up the
supersaturated subset used in this study are those proteins within the top
5% of supersaturation scores (Table S2). The classiﬁcation of supersat-
urated protein that we have used is therefore based on an estimated
score, and that proteome-wide measurements will be needed in the
future to measure these levels experimentally.
3.1.7. Deﬁnition of a vulnerability landscape of the brain to
neurodegeneration
Regions described as the most common location for initial onset of
four prevalent neurodegenerative diseases associated with aberrant ag-
gregation, were collected and together deﬁne the most vulnerable tis-
sues. Table S1 lists these regions for each disease (AD, ALS, FTD, and PD),
and associated references.
3.1.8. Deﬁnition of a set of genes downregulated in AD and ageing
Genes downregulated upon ageing and ADwere calculated previously
by including all the genes signiﬁcantly downregulated in these cases
(Ciryam et al., 2016). Corrections are made to exclude the inﬂuence of
each factor on the other, further details of calculation techniques can be
found in the original paper (Ciryam et al., 2013).
3.1.9. Relative gene expression for cell types
Data were obtained from a previous mRNA sequencing study of
human brain tissue (Hawrylycz et al., 2012). To evaluate the vulnera-
bility of different brain cell types, the relative expression was calculated
for each gene within each cell type as
E'g;c ¼
Eg;c
μg;c
(6)
where Eg,c is the expression for each gene g in a given cell type c, and μg,c
is the mean expression of that gene in a given cell type c.
3.1.10. Enrichment analysis
To evaluate enrichment, we created an ‘enrichment ratio’, which
describes the ratio between observed and expected proteins in the
metastable subproteome, for an assigned property under study
Enrichment ratio¼ MSx=MS
Px=P
¼ observed
expected
(7)
where MSx is the number of metastable subproteome members assigned
to subcellular localisation or biological process x, MS is the total number
of proteins in the metastable subproteome, Px is the number of human
proteome members assigned to subcellular localisation or biological
process x, and P is total the number of proteins in the human proteome as
a whole. We evaluated the signiﬁcance of our results using a one-tailed
Fisher exact test and Bonferroni multiple hypothesis correction. The
background dataset was downloaded from uniprot.org, with all reviewed
human proteins included (http://www.uniprot.org/downloads). This
dataset included subcellular localisation and biological process gene
ontology assignments for each protein. Protein IDs were converted be-
tween UniProt and Entrez ID using the UniProt ID mapping service. The
gene ontology (GO) project provides a controlled vocabulary describing
the biological processes a protein is involved in. Data available from the
UniProt website lists selected terms derived from the GO project.
3.1.11. Evaluation of statistical signiﬁcance
To assess the differences in the distributions of Δ scores between
various data sets, we used the nonparametric Wilcoxon/Mann-Whitney U
R. Freer et al. Heliyon 5 (2019) e02589test (Mann and Whitney, 1947), or a two-tailed t test (Fisher, 1925), as
speciﬁed in the ﬁgure captions. Because of the high number of data and
hypotheses tested in this study, we adjusted the P values to reduce the
false discovery rate (FDR). Speciﬁcally, for Figs. 2, 5, 6, 7, 9, 12, 13, and
14, we used the Benjamini-Hochberg multiple hypothesis testing
correction to control the FDR (Benjamini and Hochberg, 1995) because
this method allows the cost paid for the control of multiplicity to be kept
relatively low. More generally, from the analysis of the relationship be-
tween FDR, sensitivity, and study sample size, it is known that micro-
array studies can be susceptible to large FDR, which, besides
measurement variability, is primarily determined by the proportion of
truly differentially expressed genes, the magnitude of the true differ-
ences, and sample size (Pawitan et al., 2005; Storey and Tibshirani,
2003). Because our work relies on 3700 microarray studies (up to 900
samples from six brains), the FDR rate analysis was performed on a
relatively large sample size, allowing for rather sensitive detection of
truly differentially expressed genes. We further increased the statistical
signiﬁcance of the results and avoided a high false-negative rate by
calculating the signiﬁcance of the difference of Δ score distributions for
groups of genes. In comparison to calculating the signiﬁcance of the
differences of Δ scores of individual genes, this approach greatly reduced
the number of hypotheses in our study. These tests were performed using
the SciPy and rpy2 modules for Python.
3.1.10. Shading of cortical and subcortical brain structures on three-
dimensional representation
Figs. 4 and 13A were created using a set of three-dimensional meshes
of a human brain, which were constructed from 12 volumes acquired
using magnetic resonance imaging (Causevic et al., 2010; Klein and
Tourville, 2012; Wilhelm et al., 2014). Images were colored using the
computer graphics software Blender.
3.1.12. Creation of a three-dimensional representation of the synaptosome
Data on the proteomic contents of the synaptosome, and their relative
location and abundance in this environment, were taken from (Wilhelm
et al., 2014). The graphical model of the average presynaptic terminal
was constructed using custom-written plug-ins and scripts in the 3D
software Autodesk Maya (Autodesk Inc., San Rafael, CA). Information on
protein structures was obtained from the Uniprot database. If available,
protein data base (PDB) coordinates were used to determine the structure
of a protein. In case no PDB data for an entire protein or parts of the
protein existed, structural information from the following prediction
servers was used to create the 3D structure manually: secondary structure
(http://bioinf.cs.ucl.ac.uk/psipred/), alignment (http://web.expasy
.org/sim/), coiled coil (http://toolkit.tuebingen.mpg.de/pcoils), disor-
der (http://mbs.cbrc.jp/poodle/poodle-s.html; http://mbs.cbrc.jp/pood
le/poodle-w.html; http://mbs.cbrc.jp/poodle/poodle-l.html), trans-
membrane (http://www.ch.embnet.org/software/TMPRED_form.html),
glycosylation (http://www.glycosciences.de/modeling/glyprot/php/
main.php), domain search (http://smart.embl-heidelberg.de/index2.cgi
), homologue proteins (http://web.expasy.org/blast/).
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